Compare AU & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AU | BIO |
|---|---|---|
| Founded | 1944 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Laboratory Analytical Instruments |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.5B | 8.0B |
| IPO Year | 2023 | 1994 |
| Metric | AU | BIO |
|---|---|---|
| Price | $109.30 | $386.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $119.00 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 2.4M | 236.0K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,583,200,000.00 |
| Revenue This Year | $38.71 | $2.74 |
| Revenue Next Year | $2.89 | $3.20 |
| P/E Ratio | $23.93 | ★ N/A |
| Revenue Growth | N/A | ★ 0.65 |
| 52 Week Low | $62.55 | $236.73 |
| 52 Week High | $129.14 | $396.23 |
| Indicator | AU | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 69.94 |
| Support Level | $76.14 | $287.41 |
| Resistance Level | $113.70 | $396.23 |
| Average True Range (ATR) | 4.08 | 11.10 |
| MACD | -1.06 | -0.93 |
| Stochastic Oscillator | 53.36 | 79.56 |
Anglogold Ashanti PLC is an independent gold mining company. It has a diversified asset portfolio, including production from operations in eight countries (Argentina, Australia, Brazil, Egypt, Ghana, Guinea, the DRC, and Tanzania), supported by greenfield projects in the United States and Colombia. The company's main product is gold, which once mined, is processed into dore (unrefined gold bars) on site and then dispatched to precious metals refineries. Geographically, Anglogold generates maximum revenue from its operations in Africa (comprising operations at Kibali, Iduapriem, Obuasi, Siguiri, Geita, and Sukari mines), followed by Australia (including Sunrise Dam and Tropicana), and the Americas (comprising Cerro Vanguardia, AngloGold Ashanti Mineracao, and Serra Grande operations).
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.